| |
|
|
|
|
|
|
|||
|
Blood, 12 November 2009, Vol. 114, No. 20, pp. 4566-4574. Prepublished online as a Blood First Edition Paper on September 22, 2009; DOI 10.1182/blood-2009-03-209973.
TRANSPLANTATION Bone marrow as an alternative site for islet transplantation1 San Raffaele Diabetes Research Institute and 2 San Raffaele Telethon Institute for Gene Therapy, San Raffaele Scientific Institute, Milan, Italy; 3 Vita-Salute San Raffaele University, Milan, Italy; 4 Bone Metabolic Unit and 5 Pathology Unit, Unit of Lymphoid Malignancies, San Raffaele Scientific Institute, Milan, Italy; 6 Department of Immunology and Microbial Sciences, The Scripps Research Institute, La Jolla, CA; and 7 Dresden University of Technology, Center for Regenerative Therapies Dresden, Dresden, Germany
The liver is the current site for pancreatic islet transplantation, but has many drawbacks due to immunologic and nonimmunologic factors. We asked whether pancreatic islets could be engrafted in the bone marrow (BM), an easily accessible and widely distributed transplant site that may lack the limitations seen in the liver. Syngeneic islets engrafted efficiently in the BM of C57BL/6 mice rendered diabetic by streptozocin treatment. For more than 1 year after transplantation, these animals showed parameters of glucose metabolism that were similar to those of nondiabetic mice. Islets in BM had a higher probability to reach euglycemia than islets in liver (2.4-fold increase, P = .02), showed a compact morphology with a conserved ratio between
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2009 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||